Seattle Genetics, Pieris Launch Up-to-$1.2B Immuno-Oncology Collaboration

Seattle Genetics will partner with Pieris Pharmaceuticals to develop bispecific immuno-oncology treatments through a collaboration that could generate up to $1.2 billion-plus for Pieris, the companies said today.The companies would work to create antibody–anticalin fusion proteins for solid tumors and blood cancers by combining Seattle Genetics’ cancer targets and tumor-specific monoclonal antibodies—developed through its work on antibody–drug conjugates—with Pieris